We only have this paper's title and publication details.
Read it at the sourceAnswers are grounded in this paper and cite their sources.
A randomized trial compared pradefovir mesylate to tenofovir in chronic hepatitis B patients, suggesting pradefovir as a strong treatment option.
Pradefovir should be a highly recommended treatment option for adult patients with CHB.
No takes yet. Share an insight, caveat, or question.
Yanhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: